Biogen Inc. Stock Climbs 4.2%, Outperforms Peers

This article was automatically generated by Dow Jones using technology from Automated Insights.

Shares of Biogen Inc. advanced 4.2% to $243.24 on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index rising 0.3% to 7,712.57 and the Dow Jones Industrial Average rising 1.0% to 52,495.88.

This was the stock's second consecutive day of gains.

Biogen Inc. hit a new 52-week high, surpassing its previous peak of $240.99, which the company reached on October 15th.

The stock outperformed some of its peers, as Johnson & Johnson rose 2.2% to $259.36, Pfizer Inc. rose 2.3% to $30.11, and AbbVie Inc. rose 2.26% to $289.08.

Trading volume totaled 1.5 million, compared to the 50-day average of 980,822.

Data source: Dow Jones Market Data, FactSet

(END) Dow Jones Newswires

October 20, 2026 16:34 ET (20:34 GMT)